Clinical Trials Logo

Pulmonary Aspergillosis clinical trials

View clinical trials related to Pulmonary Aspergillosis.

Filter by:

NCT ID: NCT06447402 Recruiting - Clinical trials for Chronic Pulmonary Aspergillosis

A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis

NAB-CPA
Start date: June 3, 2024
Phase: Phase 3
Study type: Interventional
Read more »
NCT ID: NCT06244979 Not yet recruiting - Clinical trials for Allergic Bronchopulmonary Aspergillosis

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

MIRAGE
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection. The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.

NCT ID: NCT06174922 Recruiting - Clinical trials for Allergic Bronchopulmonary Aspergillosis

A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis

PICA
Start date: December 1, 2023
Phase: Phase 3
Study type: Interventional

The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to itraconazole or prednisolone monotherapy. In this study, 300 subjects aged ≥18 years with acute ABPA will be randomized to treatment with either prednisolone, itraconazole, or prednisolone plus itraconazole, all for four months each. After collecting baseline demographic, immunologic, and imaging data, the investigators will follow the patients every 2 months for the first two visits and then every four months for three visits. The primary outcome will be the proportion of subjects experiencing exacerbation (asthma or ABPA) 12 months after treatment completion.

NCT ID: NCT05982912 Recruiting - Clinical trials for Invasive Pulmonary Aspergillosis

VOC in Breath Samples for the Diagnosis of IPA

Start date: March 3, 2022
Phase:
Study type: Observational
Read more »
NCT ID: NCT05903612 Withdrawn - Asthma Clinical Trials

Allergic Bronchopulmonary Aspergillosis Prescreening Study

Start date: January 10, 2024
Phase:
Study type: Observational

This prescreening study is being conducted to diagnose ABPA in selected patients with asthma and to increase the potential number of eligible participants for the ongoing Study 601-0018 of PUR1900 in subjects with ABPA. See: NCT05667662. Additionally, this prescreening study may provide information that could assist the conduct of future studies conducted by Pulmatrix.

NCT ID: NCT05897294 Available - Clinical trials for Invasive Pulmonary Aspergillosis

Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

Start date: n/a
Phase:
Study type: Expanded Access

Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks. Duration of treatment may be extended on a case-by-case basis depending on drug availability and after discussion with the Sponsor.

NCT ID: NCT05860387 Recruiting - Clinical trials for Respiratory Infection

Early Diagnosis of Invasive Lung Aspergillosis

Start date: May 31, 2023
Phase:
Study type: Observational
Read more »
NCT ID: NCT05783544 Recruiting - Clinical trials for COPD Exacerbation Acute

Impact of A. Lumbricoides on Pulmonary Aspergillosis Development

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

The prevalence of ascariasis in COPD patients with and without concomitant pulmonary aspergillosis and in controls will be determined. To assess the influence of ascaridosis on the development of pulmonary aspergillosis in COPD patients cytokine status of patients will be studied.

NCT ID: NCT05671328 Not yet recruiting - Clinical trials for Ventilator Associated Pneumonia

Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia

ASPIC
Start date: March 2023
Phase:
Study type: Observational

Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the causes of VAP. The hypothesis of the study is that the incidence of IPA is 12.4%. For each patient presenting with a suspicion of VAP and requiring a bronchoalveolar lavage (BAL), the diagnosis of API will be evaluated by biological examinations performed on blood and BAL. Medical and surgical history as well as clinical and biological data will be collected for 28 days or until discharge from the ICU.

NCT ID: NCT05653193 Not yet recruiting - Aspergillosis Clinical Trials

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

INCAS
Start date: January 2024
Phase: Phase 2
Study type: Interventional
Read more »